Wolfgang Högler
About
In The Last Decade
Wolfgang Högler
157 papers receiving 4.7k citations
Hit Papers
Peers
Comparison fields: 5 of 141
- Orthopedics and Sports Medicine 1.2k
- Endocrinology, Diabetes and Metabolism 1.2k
- Genetics 1.1k
- Pathology and Forensic Medicine 986
- Molecular Biology 902
Countries citing papers authored by Wolfgang Högler
This map shows the geographic impact of Wolfgang Högler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wolfgang Högler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wolfgang Högler more than expected).
Fields of papers citing papers by Wolfgang Högler
This network shows the impact of papers produced by Wolfgang Högler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wolfgang Högler. The network helps show where Wolfgang Högler may publish in the future.
Co-authorship network of co-authors of Wolfgang Högler
This figure shows the co-authorship network connecting the top 25 collaborators of Wolfgang Högler. A scholar is included among the top collaborators of Wolfgang Högler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wolfgang Högler. Wolfgang Högler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 1 | |
| 3 | 0 | |
| 4 | 0 | |
| 5 | 0 | |
| 6 | 4 | |
| 7 | 1 | |
| 8 | 16 | |
| 9 | 1 | |
| 10 | 0 | |
| 11 | 4 | |
| 12 | 2 | |
| 13 | 53 | |
| 14 | BUR-CL207: An Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients from Birth to Less than 1 Year of Age with XLH. | 1 |
| 15 | 7 | |
| 16 | 6 | |
| 17 | 7 | |
| 18 | 43 | |
| 19 | 27 | |
| 20 | Fractures in Children with Chronic Inflammatory and/or Disabling Conditions: the SNAP Study | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.